Actively Recruiting
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-12-19
151
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.
CONDITIONS
Official Title
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
- Patients fit for cytoreductive surgery
- Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
- Patients selected for interval cytoreductive surgery after neoadjuvant chemotherapy
You will not qualify if you...
- Patients with pre-operative Stage I-II disease confined to the pelvis
- Patients unfit for surgery
- Lack of information about patients' surgical outcomes and clinicopathological characteristics
- Patients with low-grade serous ovarian cancer, clear cell, mucinous, or non-epithelial histologic subtypes if available
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica
Roma, Italy, 00168
Actively Recruiting
Research Team
L
Liat Hogen, MD
CONTACT
F
Ferdous Parveen, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here